The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2022-05-19), Orgenesis's share price is $2.10. Orgenesis's Book Value per Share for the quarter that ended in Dec. 2021 was $1.59. Hence, Orgenesis's PB Ratio of today is 1.32.
Good Sign:
Orgenesis Inc stock PB Ratio (=1.33) is close to 10-year low of 1.33
The historical rank and industry rank for Orgenesis's PB Ratio or its related term are showing as below:
ORGS'
s PB Ratio Range Over the Past 10 Years
Min: 1.32 Med: 3.45 Max: 18.37
Current: 1.32
During the past 13 years, Orgenesis's highest PB Ratio was 18.37. The lowest was 1.32. And the median was 3.45.
ORGS's PB Ratio is ranked better than 71.71% of 1414
companies
in the Biotechnology industry
Industry Median: 2.25
vs ORGS: 1.32
During the past 12 months, Orgenesis's average Book Value Per Share Growth Rate was -27.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -5.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 1.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Orgenesis was 14.90% per year. The lowest was -681.30% per year. And the median was -104.00% per year.
Back to Basics: PB Ratio
Orgenesis PB Ratio Historical Data
The historical data trend for Orgenesis's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Orgenesis Annual Data
Trend
Nov12
Nov13
Nov14
Nov15
Nov16
Nov17
Nov18
Dec19
Dec20
Dec21
PB Ratio
3.14
3.17
13.75
2.07
1.82
Orgenesis Quarterly Data
Feb17
May17
Aug17
Nov17
Feb18
May18
Aug18
Nov18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
PB Ratio
2.07
2.56
2.42
2.82
1.82
Competitive Comparison
For the Biotechnology subindustry, Orgenesis's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orgenesis PB Ratio Distribution
For the Biotechnology industry and Healthcare sector, Orgenesis's PB Ratio distribution charts can be found below:
* The bar in red indicates where Orgenesis's PB Ratio falls into.
Orgenesis PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Orgenesis's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Orgenesis PB Ratio Related Terms
Thank you for viewing the detailed overview of Orgenesis's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.01(0.47%) Volume: 26,704 10:39AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ORGS has been successfully added to your 
